In an adult with chronic obstructive pulmonary disease, is low‑dose aspirin (75–81 mg daily) appropriate for secondary cardiovascular prevention, and what contraindications (aspirin‑exacerbated respiratory disease, active gastrointestinal ulcer, high bleeding risk) must be considered?

Aspirin in COPD for Secondary Cardiovascular Prevention

Direct Recommendation

Low-dose aspirin (75–100 mg daily) is appropriate and strongly indicated for secondary cardiovascular prevention in adults with COPD who have established atherosclerotic cardiovascular disease, as the cardiovascular benefit substantially outweighs bleeding risk in this setting. 1, 2

---

Indication Framework

When Aspirin IS Indicated in COPD Patients

Secondary prevention (established ASCVD):

• Aspirin 75–100 mg once daily is the standard of care for patients with prior myocardial infarction, coronary artery disease, or ischemic stroke 1
• The reduction in fatal and non-fatal serious vascular events (15 fewer events per 1000 patients treated annually) far exceeds the increase in major gastrointestinal and extracranial bleeding (0.03% absolute increase per year) 1
• COPD itself is an independent risk factor for ASCVD, making secondary prevention particularly important in this population 3

Dosing in COPD patients with established ASCVD:

• Standard low-dose aspirin 75–100 mg daily (81 mg in the U.S.) is as effective as higher doses with fewer side effects 1, 2
• A 2025 analysis of the ADAPTABLE trial found no significant difference in cardiovascular outcomes between 81 mg and 325 mg aspirin in COPD/asthma patients with established ASCVD (adjusted HR 1.15,95% CI 0.92–1.43) 3
• However, COPD/asthma patients on 81 mg had a significantly higher stroke risk compared to 325 mg (adjusted HR 2.41,95% CI 1.27–4.57), suggesting potential consideration of higher dosing specifically for stroke prevention in this subgroup 3

When Aspirin Is NOT Indicated in COPD Patients

Primary prevention:

• Aspirin should not be routinely used for primary prevention in COPD patients without established ASCVD 2, 4
• Recent trials (ASCEND, ARRIVE, ASPREE) demonstrate that bleeding risk equals or exceeds cardiovascular benefit when patients receive contemporary statin and blood pressure therapy 2
• The number needed to treat to cause a major bleed (210) is lower than the number needed to prevent an ASCVD event (265) in unselected populations 2

---

Absolute Contraindications in COPD Patients

Aspirin-exacerbated respiratory disease (AERD):

• This is a distinct clinical syndrome characterized by asthma, chronic rhinosinusitis with nasal polyps, and respiratory reactions to aspirin and NSAIDs 1
• AERD is a contraindication to aspirin use regardless of cardiovascular indication
• COPD alone without aspirin sensitivity is not a contraindication to aspirin 1

Active gastrointestinal ulcer or recent bleeding:

• Prior gastrointestinal bleeding or active peptic ulcer disease is an absolute contraindication 2
• History of GI bleeding increases bleeding risk to approximately 5 per 1000 person-years 2, 4

High bleeding risk factors:

• Age >70 years (bleeding risk outweighs benefit even for secondary prevention in some guidelines, though ESC still supports use) 2, 4
• Thrombocytopenia or known bleeding disorder 2
• Concurrent anticoagulation (warfarin or DOACs) 2
• Regular NSAID use 2
• Severe liver disease 2
• Chronic kidney disease (increases bleeding risk substantially) 2
• Uncontrolled hypertension 2

---

COPD-Specific Considerations

Beta-blocker caution (not aspirin-related but relevant to cardiovascular management):

• The 2024 ESC guidelines note that beta-blockers should be used with caution in COPD patients with chronic coronary syndromes, but this does not apply to aspirin 1

Lack of evidence for aspirin to prevent COPD exacerbations:

• Observational studies suggesting aspirin reduces COPD exacerbations and mortality are affected by immortal time bias, collider-stratification bias, and exposure misclassification 5
• A 2021 systematic review found all eight observational studies reporting benefit were methodologically flawed, with biases known to exaggerate drug effectiveness 5
• A 2015 retrospective study found no anti-infection effects of aspirin in COPD and paradoxically increased exacerbation rates (p = 0.008) 6
• The APPLE COPD-ICON2 trial is investigating platelet function in COPD but has not yet reported outcomes 7

---

Clinical Algorithm for Aspirin Use in COPD

Step 1: Determine cardiovascular disease status

• Established ASCVD (prior MI, stroke, coronary disease)?
  • YES → Proceed to Step 2
  • NO → Aspirin not indicated for primary prevention 2, 4

Step 2: Screen for absolute contraindications

• Active GI bleeding or peptic ulcer? 2
• Known aspirin-exacerbated respiratory disease? 1
• Bleeding disorder or thrombocytopenia? 2
• Concurrent anticoagulation? 2
• If ANY present → Aspirin contraindicated
• If NONE present → Proceed to Step 3

Step 3: Assess relative bleeding risk

• Age >70 years? 2
• Chronic kidney disease? 2
• Regular NSAID use? 2
• Uncontrolled hypertension? 2
• If multiple factors present → Consider gastroprotection with PPI or alternative antiplatelet strategy
• If low bleeding risk → Initiate aspirin 75–100 mg daily 1

Step 4: Monitor and adjust

• For standard secondary prevention: 81 mg daily 1, 2
• For COPD/asthma patients with prior stroke: consider 325 mg daily based on ADAPTABLE subgroup analysis 3
• Reassess bleeding risk annually 2

---

Common Pitfalls to Avoid

Do not withhold aspirin from COPD patients with established ASCVD based solely on their lung disease:

• COPD is not a contraindication to aspirin unless aspirin-exacerbated respiratory disease is documented 1
• The cardiovascular benefit in secondary prevention far exceeds any theoretical respiratory concern 1, 2

Do not prescribe aspirin for COPD exacerbation prevention:

• No rigorous evidence supports this indication, and observational studies are severely biased 5, 6

Do not use aspirin for primary prevention in COPD patients based on elevated ASCVD risk scores alone:

• The 10% 10-year ASCVD risk threshold is no longer an automatic indication for aspirin 2
• Bleeding risk in COPD patients (often older, with comorbidities) may exceed cardiovascular benefit 2, 4

Do not overlook stroke risk in COPD/asthma patients:

• The ADAPTABLE subgroup analysis suggests 81 mg may be insufficient for stroke prevention in this population 3
• Consider 325 mg daily in COPD/asthma patients with prior stroke if bleeding risk is acceptable 3